Sarepta Therapeutics, Inc. (SRPT)

From the record

Sarepta Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Sarepta Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $5 million in fiscal 2016 to $2.2 billion in fiscal 2025, up 94.9% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 1 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Sarepta Therapeutics, Inc. lost about 63 cents for every dollar of shareholders' money, and gross profitability: its products earned about 65 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 66 cents per dollar of assets, and net share issuance: its share count grew 5.3% over the year (the filed statements).

From the record

Sarepta Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $2.2 billion in fiscal 2025 ranks in the top 9% by size; a net margin of -32.5% ranks in the top 37%; revenue growth of 33.1% a year over the last 3 filed years ranks in the top 29% (its annual reports).

From the record

Sarepta Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Severino, Michael (Chief Executive Officer, as filed), filing under that title since 2026-07-29, 4 months (bottom 4% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 5.5 years (bottom 46%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Sarepta Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $801 million against debt of $829 million leaves -0.8% of its assets as net cash, bottom 13% of its family; cash from operations less capital spending is -14% of revenue (top 35%); a gross margin of 98.8% (top 3%); research spending of 69.2% of revenue (bottom 45%) (its annual report).

From the record

Sarepta Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 33.1% a year over the last three filed years against 94.9% over all 10, slowing (bottom 9% of its family); the newest year grew 15.6% (top 41%); research spending grew 20.2% a year (top 23%); capital spending grew 49% a year (top 15%) (its annual reports). Sarepta Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Sarepta Therapeutics, Inc.'s newest year against its own record: revenue of $2.2 billion in fiscal 2025 came in 19% below the $2.7 billion its prior three years' pace pointed to (bottom 32% of its family); net income of $713 million against a prior three-year average of $335 million (bottom 13%); a net margin of -32.5% against -35.4% before (bottom 40%) (its annual reports).